These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 10368873)
41. 3,4-N-methlenedioxymethamphetamine-induced hypophagia is maintained in 5-HT1B receptor knockout mice, but suppressed by the 5-HT2C receptor antagonist RS102221. Conductier G; Crosson C; Hen R; Bockaert J; Compan V Neuropsychopharmacology; 2005 Jun; 30(6):1056-63. PubMed ID: 15668722 [TBL] [Abstract][Full Text] [Related]
42. Behavioural profile of selective ligands for mGlu7 and mGlu8 glutamate receptors in agonistic encounters between mice. Navarro JF; de Castro V; Martín-López M Psicothema; 2009 Aug; 21(3):475-9. PubMed ID: 19622332 [TBL] [Abstract][Full Text] [Related]
43. A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy"). Thompson MR; Callaghan PD; Hunt GE; Cornish JL; McGregor IS Neuroscience; 2007 May; 146(2):509-14. PubMed ID: 17383105 [TBL] [Abstract][Full Text] [Related]
44. Methylenedioxymethamphetamine (Ecstasy) decreases neutrophil activity and alters leukocyte distribution in bone marrow, spleen and blood. de Paula VF; Ribeiro A; Pinheiro ML; Sakai M; Lacava MC; Lapachinske SF; Moreau RL; Palermo-Neto J Neuroimmunomodulation; 2009; 16(3):191-200. PubMed ID: 19246942 [TBL] [Abstract][Full Text] [Related]
45. Acute and sensitized response to 3,4-methylenedioxymethamphetamine in rats: different behavioral profiles reflected in different patterns of Fos expression. Colussi-Mas J; Schenk S Eur J Neurosci; 2008 Nov; 28(9):1895-910. PubMed ID: 18973603 [TBL] [Abstract][Full Text] [Related]
46. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Dumont GJ; Sweep FC; van der Steen R; Hermsen R; Donders AR; Touw DJ; van Gerven JM; Buitelaar JK; Verkes RJ Soc Neurosci; 2009; 4(4):359-66. PubMed ID: 19562632 [TBL] [Abstract][Full Text] [Related]
47. Interactions between 3,4-methylenedioxymethamphetamine and ethanol in humans and rodents. Mohamed WM; Hamida SB; de Vasconcelos AP; Cassel JC; Jones BC Neuropsychobiology; 2009; 60(3-4):188-94. PubMed ID: 19893335 [TBL] [Abstract][Full Text] [Related]
48. MDMA elicits behavioral and neurochemical sensitization in rats. Kalivas PW; Duffy P; White SR Neuropsychopharmacology; 1998 Jun; 18(6):469-79. PubMed ID: 9571655 [TBL] [Abstract][Full Text] [Related]
49. Role of AMPA glutamate receptors in the conditioned rewarding effects of MDMA in mice. García-Pardo MP; Miñarro J; Aguilar MA Behav Brain Res; 2018 Jul; 347():57-60. PubMed ID: 29526785 [TBL] [Abstract][Full Text] [Related]
50. Acute administration of 3,4-methylenedioxymethamphetamine induces profound hyperthermia, blood-brain barrier disruption, brain edema formation, and cell injury. Sharma HS; Ali SF Ann N Y Acad Sci; 2008 Oct; 1139():242-58. PubMed ID: 18991870 [TBL] [Abstract][Full Text] [Related]
51. Sensitization to MDMA locomotor effects and changes in the functionality of 5-HT(2A) and D₂ receptors in mice. Varela MJ; Brea J; Loza MI; Maldonado R; Robledo P Behav Pharmacol; 2011 Aug; 22(4):362-9. PubMed ID: 21712712 [TBL] [Abstract][Full Text] [Related]
52. Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination. Baker LE; Taylor MM Pharmacol Biochem Behav; 1997 Aug; 57(4):737-48. PubMed ID: 9259001 [TBL] [Abstract][Full Text] [Related]
53. Time course analysis of the discriminative stimulus effects of the optical isomers of 3,4-methylenedioxymethamphetamine (MDMA). Baker LE; Virden TB; Miller ME; Sullivan CL Pharmacol Biochem Behav; 1997 Oct; 58(2):505-16. PubMed ID: 9300612 [TBL] [Abstract][Full Text] [Related]
54. 3,4-Methylenedioxymethamphetamine produces glycogenolysis and increases the extracellular concentration of glucose in the rat brain. Darvesh AS; Shankaran M; Gudelsky GA J Pharmacol Exp Ther; 2002 Apr; 301(1):138-44. PubMed ID: 11907167 [TBL] [Abstract][Full Text] [Related]
55. Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. Baggott MJ; Coyle JR; Siegrist JD; Garrison KJ; Galloway GP; Mendelson JE J Psychopharmacol; 2016 Apr; 30(4):378-87. PubMed ID: 26880224 [TBL] [Abstract][Full Text] [Related]
56. Prosocial effects of MDMA: A measure of generosity. Kirkpatrick M; Delton AW; Robertson TE; de Wit H J Psychopharmacol; 2015 Jun; 29(6):661-8. PubMed ID: 25735993 [TBL] [Abstract][Full Text] [Related]
57. A comparison of the reinforcing efficacy of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") with cocaine in rhesus monkeys. Lile JA; Ross JT; Nader MA Drug Alcohol Depend; 2005 May; 78(2):135-40. PubMed ID: 15845316 [TBL] [Abstract][Full Text] [Related]
58. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. Mas M; Farré M; de la Torre R; Roset PN; Ortuño J; Segura J; Camí J J Pharmacol Exp Ther; 1999 Jul; 290(1):136-45. PubMed ID: 10381769 [TBL] [Abstract][Full Text] [Related]
59. [Immunomodulator properties of ecstasy (MDMA)]. Pacifici R; Zuccaro P; Farré M; Pichini S; Di Carlo S; Roset PN; Ortuño J; Segura J; Hernández-López C; De La Torre R Ann Ist Super Sanita; 2000; 36(1):69-75. PubMed ID: 11070610 [TBL] [Abstract][Full Text] [Related]